Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3239MR)

This product GTTS-WQ3239MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3239MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9349MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ9354MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ12782MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ12393MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ11518MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ11473MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ14041MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ4284MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW